Literature DB >> 1563378

Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.

M Jonsson1, M Walder.   

Abstract

The i.v. and i.m. dose pharmacokinetics of ceftazidime 1 g b.i.d. were investigated in steady state in 52 consecutive cases of hospitalised patients with underlying diseases and serious supervening bacterial infections. Following i.v. bolus injection, serum concentrations of greater than 4 mg/l persisted for 8 h in all patients. Compared to values found in younger patients studied previously, clearance was markedly reduced in the elderly, t1/2 beta more than doubled, the area under the curve four times enlarged and the apparent volume of distribution reduced. The values obtained in serum after i.m. injection were similar, though the peak concentration was delayed by about 2 h. The serum uptake was approximately 70%, and serum concentration was greater than 4 mg/l for 8 h. The concentrations in tissue fluid after i.v. administration were similar to those in serum, but the penetration into tissue fluid was slower and only 20% of that reported previously for young people. The elimination was slow, with greater than 4 mg/l maintained for 7 h. Tissue concentrations after i.m. injection were almost comparable with those after i.v. injection, but lagged behind by about 1 h. In conclusion, suitable concentrations in blood and tissue are attained with 1 g ceftazidime b.i.d., whether administered by the i.v. or i.m. route.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563378     DOI: 10.1007/bf01971265

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Penetration of ceftazidime into extracellular fluid in patients.

Authors:  B Hoffstedt; M Walder
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

2.  Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe.

Authors:  J Gundersen
Journal:  Acta Chir Scand Suppl       Date:  1972

3.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 4.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  Pharmacokinetics of ceftazidime in patients with renal insufficiency.

Authors:  L S Welage; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

6.  Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  The penetration of ceftazidime into extravascular fluid.

Authors:  D M Ryan; U Mason; S M Harding
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

8.  The pharmacokinetics of ceftazidime in normal and impaired renal function.

Authors:  D Höffler; P Koeppe; K J Williams
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

9.  Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections.

Authors:  K G Naber; F Kees; H Grobecker
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

10.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  3 in total

1.  Pharmacodynamics and alternative antimicrobial dosing regimens.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1995-01

2.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 3.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.